A new meta-analysis suggests that sodium-glucose cotransporter-2 (SGLT2) inhibitors can improve clinical outcomes in patients with heart failure (HF), type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), supporting calls to adopt their use across the three patient populations.